HOXD13 and leukemia: Mutations in the C-terminal partners of NUP98 fusions like NUP98-NSD1, NUP98-JARID1A, NUP98-DDX10, and NUP98-HOXD13 abrogated the leukemic transformation induced by these fusion proteins, indicating the importance of targeting the functional properties of the C-terminal partner gene to treat these leukemias [15,17,18,19].